EyePoint Pharmaceuticals Inc’s recently made public that its SVP & Chief Commercial Officer Jones David Scott unloaded Company’s shares for reported $5954.0 on Feb 02 ’24. In the deal valued at $28.49 per share,209 shares were sold. As a result of this transaction, Jones David Scott now holds 37,962 shares worth roughly $0.81 million.
Then, Paggiarino Dario A. sold 49,325 shares, generating $1,265,539 in total proceeds. Upon selling the shares at $25.66, the Chief Medical Officer now owns 36,505 shares.
Before that, Jones David Scott sold 26,017 shares. EyePoint Pharmaceuticals Inc shares valued at $660,370 were divested by the SVP & Chief Commercial Officer at a price of $25.38 per share. As a result of the transaction, Jones David Scott now holds 37,962 shares, worth roughly $0.81 million.
JP Morgan initiated its EyePoint Pharmaceuticals Inc [EYPT] rating to an Overweight in a research note published on January 22, 2024; the price target was $35. A number of analysts have revised their coverage, including Mizuho’s analysts, who began to cover the stock in early November with a ‘”a Buy”‘ rating. Robert W. Baird began covering EYPT with “an Outperform” recommendation on April 21, 2023. Chardan Capital Markets started covering the stock on July 07, 2022. It rated EYPT as “a Buy”.
Price Performance Review of EYPT
On Monday, EyePoint Pharmaceuticals Inc [NASDAQ:EYPT] saw its stock fall -5.21% to $21.28. Over the last five days, the stock has gained 2.65%. EyePoint Pharmaceuticals Inc shares have fallen nearly -7.92% since the year began. Nevertheless, the stocks have risen 449.87% over the past one year. While a 52-week high of $30.99 was reached on 02/08/24, a 52-week low of $3.36 was recorded on 01/11/24. SMA at 50 days reached $24.60, while 200 days put it at $15.77. A total of 0.58 million shares were traded, compared to the trading of 0.67 million shares in the previous session.
Levels Of Support And Resistance For EYPT Stock
The 24-hour chart illustrates a support level at 20.73, which if violated will result in even more drops to 20.17. On the upside, there is a resistance level at 22.07. A further resistance level may holdings at 22.85. The Relative Strength Index (RSI) on the 14-day chart is 44.03, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.18, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 55.71%. Stochastics %K at 67.80% indicates the stock is a holding.
The most recent change occurred on March 01, 2021 when Cowen began covering the stock and recommended ‘”an Outperform”‘ rating along with a $25 price target.
